|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic α7 and σ1 receptors in a rat model of Parkinson’s disease显示文摘To date there is no treatment able to stop or slow down the loss of dopaminergic neurons that characterizes Parkinson’s disease.It was recently observed in a rodent model of Alzheimer’s disease that the interaction between the α7 subtype of nicotinic acetylcholine receptor(α7-nAChR)and sigma-1 receptor(σ1-R)could exert neuroprotective effects through the modulation of neuroinflammation which is one of the key components of the pathophysiology of Parkinson’s disease.In this context,the aim of the present study was to assess the effects of the concomitant administration of N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-furo[2,3-c]pyridine-5-carboxamide(PHA)543613 as an α7-nAChR agonist and 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate(PRE)-084 as aσ1-R agonist in a well-characterized 6-hydroxydopamine rat model of Parkinson’s disease.The animals received either vehicle separately or the dual therapy PHA/PRE once a day until day 14 postlesion.Although no effect was noticed in the amphetamine-induced rotation test,our data has shown that the PHA/PRE treatment induced partial protection of the dopaminergic neurons(15-20%),assessed by the dopamine transporter density in the striatum and immunoreactive tyrosine hydroxylase in the substantia nigra.Furthermore,this dual therapy reduced the degree of glial activation consecutive to the 6-hydroxydopamine lesion,i.e,the 18 kDa translocation protein density and glial fibrillary acidic protein staining in the striatum,and the CD11b and glial fibrillary acidic protein staining in the substantia nigra.Hence,this study reports for the first time that concomitant activation of α7-nAChR andσ1-R can provide a partial recovery of the nigro-striatal dopaminergic neurons through the modulation of microglial activation.The study was approved by the Regional Ethics Committee(CEEA Val de Loire n°19)validated this protocol(Authorization N°00434.02)on May 15,2014. | Steven Vetel Laura Foucault-Fruchard Claire Tronel Frédéric Buron Jackie Vergote Sylvie Bodard Sylvain Routier Sophie Sérrière Sylvie Chalon | 2021 | Neural Regeneration Research2021，16，6： | 3 |
| 2 | Alpha-7 nicotinic acetylcholine receptor agonist treatment in a rat model of Huntington's disease and involvement of heme oxygenase-1显示文摘Neuroinflammation is a common element involved in the pathophysiology of neurodegenerative diseases.We recently reported that repeated alpha-7 nicotinic acetylcholine receptor(α7 n ACh R) activations by a potent agonist such as PHA 543613 in quinolinic acid-injured rats exhibited protective effects on neurons.To further investigate the underlying mechanism,we established rat models of early-stage Huntington's disease by injection of quinolinic acid into the right striatum and then intraperitoneally injected 12 mg/kg PHA 543613 or sterile water,twice a day during 4 days.Western blot assay results showed that the expression of heme oxygenase-1(HO-1),the key component of the cholinergic anti-inflammatory pathway,in the right striatum of rat models of Huntington's disease subjected to intraperitoneal injection of PHA 543613 for 4 days was significantly increased compared to the control rats receiving intraperitoneal injection of sterile water,and that the increase in HO-1 expression was independent of change in α7 n ACh R expression.These findings suggest that HO-1 expression is unrelated to α7 n ACh R density and the increase in HO-1 expression likely contributes to α7 n ACh R activation-related neuroprotective effect in early-stage Huntington's disease. | Laura Foucault-Fruchard Claire Tronel Sylvie Bodard Zuhal Gulhan Julie Busson Sylvie Chalon Daniel Antier | 2018 | Neural Regeneration Research2018，13，4： | 2 |
| 3 | Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor alpha mRNA显示文摘 | Gueydan C Droogmans L Chalon P | 1999 | J Biol Chem1999，274，4： | 1 |
| 4 | Clinical effects of beta-adrenergic blockade in chronic heart failure:a meta-analysis of doubleblind,placebo-controlled,randomized trials显示文摘 | Lechat P Packer M Chalon S | 1998 | Circulation1998，98，： | 1 |
| 5 | Stable carbon isotopes and the metabolism of the terrestrial devonian organism spongiophyton显示文摘 | FLETCHER B J BEERLING D J CHALONER W G | 2004 | Geobiology2004，2，： | 1 |
| 6 | Problem-based learning, description of a pedagogical method leading to evidence-based medicine显示文摘 | Chalon P Delvenne C Pasleau F | 2000 | Rev Med Liege2000，55，： | 1 |
| 7 | Skin ageing:clinical and his- topathologic study of permanent and reducible wrinkles 显示文摘 | Bosset S Barr6 P Chalon A | 2002 | Eur J Dermatol2002，12，3： | 1 |
| 8 | Clinical effects of beta-adrenergic blockade in chronic heart failure:a meta- analysis of double ~ blind, placebo- controlled, randomized trials显示文摘 | Lechat P Packer M Chalon S | 1998 | Circulation1998，98，： | 1 |
| 9 | Clinical effects of beta-adrenergic blockade in chronic heart failure:a meta-analysis of double-blind,placebo-controlled,randomized trials显示文摘 | Lechat P Packer M Chalon S | | 0，，12： | 1 |
| 10 | Development of a pamphlet: in troducing advance directives to hemodialysis patients and their fam- ilies显示文摘 | Tigert J Chaloner N Scarr B | 2005 | Cannt Journal2005，15，1： | 1 |
| 11 | Meta-analysis of randomized clinical trials on beta-blocker treatment in heart failure显示文摘 | Chalon S Cucherat M | 1996 | Circulation1996，94，： | 1 |
| 12 | Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses 显示文摘 | Minty A Chalon P Derocq M | 1993 | Nature1993，362，： | 1 |
| 13 | The impact of atmospheric CO2 and temperature change on stomatal density: observations from Quercus robur Larnmas leaves 显示文摘 | Beerling D J Chaloner W G | 1993 | Annals of Botany1993，71，： | 1 |
| 14 | Astrocytes,cells involved in neuro-immune interactions in the central nervous system 显示文摘 | Giraudon P Malcus C Chalon A | 2003 | J Soc Biol2003，197，2： | 1 |
| 15 | ClinicaleffectsofB-adrenergy-icblockadeinchronilitlfailure显示文摘 | LeehalP PackerM ChalonS eta1 | 1998 | Circulation1998，98，： | 1 |
| 16 | Bayesian experimentaldesign: A review显示文摘 | Chaloner K Yerdinelli I | 1995 | Statistical Science1995，10，3： | 1 |
| 17 | Clinical effects of β-adrenergic blokade in chronic heart failure 显示文摘 | Lechat P Packer M Chalon S a al | 1998 | Circulation1998，98，： | 1 |
| 18 | D-and C-optimal designs for exponential regression models used in viral dynamics and other applica tions 显示文摘 | Han C Chaloner K | 2003 | Journal of Statistical Planning and Inference2003，115，2： | 1 |
| 19 | Meta-analysis of randomized clinical trials on beta-blocker treatment in heart failure显示文摘 | Chalon S Cucheat M | 1996 | Circulation1996，94，： | 1 |
| 20 | Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson′s disease显示文摘 | Chalon S Emond P Bodard S | 1999 | Synapse1999，31，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员